Company Overview and News
Airwork Holdings will quit the NZX main board on November 15 now that Rifa Jair Company, a unit of China's Zhejiang Rifa Holding, has exercised its compulsory acquisition rights in full takeover over the aviation services firm.
Foreigners got approval to buy $2.7 billion worth of New Zealand assets so far this year, up $1b on this time last year, with the biggest deal being the sale of kiwi plastics business Sistema to American interests.
New Zealand shares shrugged off the post-election vacuum to hit a record high today, despite a lack of corporate news, with Tourism Holdings, Synlait Milk and Kathmandu Holdings gaining.
New Zealand shares rose, following Asia higher, as blue chip stocks including Spark New Zealand and Fisher & Paykel Healthcare helped drag the benchmark index up, offsetting a bigger number of smaller firms declining.
Airwork Holdings, the Auckland-based aircraft services business, lifted profit 9.5 per cent in the first half as it awaits the outcome of a partial takeover offer from Chinese group Zhejiang Rifa Holding Group.
The NZX has been hit by a serious bout of takeover fever, with bids for Tower and TeamTalk this week. This follows full or partial offers for Abano Healthcare, Airwork Holdings, Antipodes Gold and Hellaby Holdings in recent months and the strong possibility that Tenon will delist after the sale of its main business.
There is widespread apprehension regarding the sale of UDC Finance, the country's largest finance company, to China's HNA Group. This is because UDC is an important lender to domestic industrial companies, because it may have to raise its lending rates and because little is known about the purchaser.
New Zealand shares edged higher, led by A2 Milk Co after it reassured the market about its infant formula business, while Tourism Holdings gained on a US acquisition. Intueri Education Group sank by a fifth after missing out on Australian government funding.
Grant Samuel has come in for a second barracking in the space of a month with HealthCare Partners, which accused the independent adviser of plumping up the valuation of Abano Healthcare.
Zhejiang Rifa Holding Group said it has acceptances for 59 per cent of Airwork Holdings in its partial takeover of the Auckland-based aircraft services business.
Zhejiang Rifa Holding Group has set out its bid for a partial takeover of Airwork Holdings, the Auckland-based aircraft services business, telling shareholders that it will seek to grow Airwork's presence in emerging markets such as Asia and Latin America.
Chinese company Zhejiang Rifa Holding Group (Rifa) has entered an agreement to acquire New Zealand firm Airwork Holdings Limited, a supplier of maintenance, repair, and overhaul (MRO) services for military/commercial helicopters and fixed-wing aircraft and related engines.
First NZ Capital has increased its target price for specialist aviation company Airwork Holdings in response to the takeover lock-up deed between China's Zhejiang Rifa Holding Group (RIFA) and Airwork's major shareholders.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...
as of ET